Patents Examined by Lester L. Lee
  • Patent number: 5352659
    Abstract: Disclosed are a peptide represented by formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein M represents a mercaptoacyl group; P, Q, R, S, T, U, V, W, X, Y and Z each represent amino acid residues, wherein an amino acid side chain of Y is either a substituted saturated aliphatic hydrocarbon group having 1 to 15 carbon atoms or an unsubstituted saturated aliphatic hydrocarbon group having 4 to 15 carbon atoms other than (1S)-1-methylpropyl; (2) a method for producing the above-mentioned peptide or the salt thereof, which comprises subjecting a peptide represented by formula (II) or a salt thereof to an oxidation reaction:M-P-Cys-Q-R-S-T-Asp-U-Glu-Cys-Val-Tyr-V-Cys-His-W-X-Y-Ile-Z-OH(II)wherein M, P, Q, R, S, T, U, V, W, X, Y and Z are as diefined above; and (3) use of the above-mentioned peptide or the pharmaceutically acceptable salt thereof as an anti-endothelin agent.
    Type: Grant
    Filed: February 14, 1992
    Date of Patent: October 4, 1994
    Assignee: Takeda Chemical Industries
    Inventors: Mitsuhiro Wakimasu, Takashi Kikuchi, Kazuki Kubo
  • Patent number: 5352665
    Abstract: A medicament for prevention and remedy of diseases caused by the infection of viruses is disclosed, which is characterized by containing as an effective ingredient thereof a nonapeptide having the following amino acid configuration:pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn or an ester and an amide at the carboxyl group of the C-terminal of the asparagine or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: October 4, 1994
    Assignee: Mitsui Toatsu Chemicals, Incorporated
    Inventors: Akira Awaya, Hisashi Kobayashi, Yusaku Ishizuka, Hayao Abe
  • Patent number: 5350741
    Abstract: An enteric formulation for a proteinous drug which protects it from enzymatic degradation and promotes its uptake by the intestinal tract when administered orally, comprises either a solid mass of an intimate mixture of the drug, a nontoxic nonionic surfactant, and an enteric material, or a solid mass of an intimate mixture of the drug with the nonionic surfactant covered by a discrete enteric coating.
    Type: Grant
    Filed: May 26, 1992
    Date of Patent: September 27, 1994
    Inventor: Kanji Takada
  • Patent number: 5348944
    Abstract: Compounds of the formula ##STR1## useful as antihypertensive agents are disclosed.
    Type: Grant
    Filed: April 4, 1988
    Date of Patent: September 20, 1994
    Assignee: Schering Corporation
    Inventors: Elijah H. Gold, Bernard R. Neustadt, Elizabeth M. Smith
  • Patent number: 5348943
    Abstract: Methods and compositions for (a) improving and/or maintaining the health of skin, and (b) increasing subcutaneous fat in warm-blooded animals are disclosed. The methods utilize an effective amount of a composition comprising GHL--Cu or a derivative of GHL--Cu.
    Type: Grant
    Filed: August 3, 1992
    Date of Patent: September 20, 1994
    Assignee: ProCyte Corporation
    Inventor: Loren R. Pickart
  • Patent number: 5349050
    Abstract: Disclosed is a novel peptide having one of the formulae: ##STR1## (A and B are the amino acids: wherein if A is D- or L-Pro, B is Hat or Cit;if A is D-Pro, B is D-Arg, andif B is D- or L-Arg, A is Sat, Pip, Aze or Arg)Asn-A-L- (D-)Pro-Arg- (Gly)n (A is Set, Thr or Ala, n is 1 or 0)A-Ser-Pip-Arg (A is Pro-Asn-, Asn- or Pro-) ##STR2## (A is cyclopentylcarbonyl, Pro or pGlu; B is Gly or .beta.-Ala, W is a hydrogen atom or a group having the formula:or a peptide having the formula: ##STR3## wherein A and B have the same meanings as mentioned above, respectively pGlu-Asn-Ser-A-B-(Gly)n (A is Aze, D- or L-Pro, Pip or Sat, B is D- or L-Arg, Cit, Hat, Lys or Orn, n is 1 or 0) andPro- (Ash)m-Set-L- (D-)Pro-Arg- (Gly) n (m and n are independently 0 or 1)their functional derivatives, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 18, 1992
    Date of Patent: September 20, 1994
    Assignees: Nippon Chemiphar Co., Ltd., Fujirebio Kabushiki Kaisha
    Inventors: Mitsuo Masaki, Masaki Uehara, Kenji Hirate, Yoshikazu Isowa, Yoshiaki Sato, Yoshiharu Nakashima
  • Patent number: 5346888
    Abstract: An alkyl ester of dipeptide comprising natural or synthetic L-amino acids with hydrophobic side chains is provided herein. Preferable amino acids are leucine, phenylalanine valine, isoleucine, alanine, proline, glycine or aspartic acid beta methyl ester. Preferable dipeptides are L-leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-leucyl L-isoleucine, L-phenylalanyl L-phenylalanine, L-valyl L-leucine, L-leucyl L-alanine, L-valyl L-valine, L-phenylalanyl L leucine, L prolyl L-leucine, L-leucyl L-valine, L-phenylalanyl L-valine, L glycyl L-leucine, L-leucyl L-glycine or L-aspartyl beta methyl ester L-phenylalanine. Most preferable dipeptides are L-leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-phenylalanyl L-leucine, L-leucyl L-isoleucine L-phenylalanyl L-phenylalanine and L-valyl L-leucine.
    Type: Grant
    Filed: December 21, 1992
    Date of Patent: September 13, 1994
    Assignee: Board of Regents, The University of Texas System
    Inventors: Peter E. Lipsky, Dwain L. Thiele
  • Patent number: 5344822
    Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering a lipid into which the endotoxin of concern is associated, preferably together with a peptide which is not an apolipoprotein. Preferably, the two components are administered in the form of a reconstituted particle, although this is by no means required.
    Type: Grant
    Filed: August 12, 1992
    Date of Patent: September 6, 1994
    Assignee: The Rogosin Institute
    Inventors: Daniel M. Levine, Thomas S. Parker, Albert L. Rubin
  • Patent number: 5340798
    Abstract: The present invention comprises fibrinogen receptor antagonist compounds, compositions containing them and methods for using them to inhibit fibrinogen binding to blood platelets. Compounds of the invention have the following formula ##STR1## wherein Z is ##STR2## X is COOH, CH.sub.2 SH or SH; R.sup.1 is Y--R.sup.3, wherein R.sup.3 is alkyl and Y is amino, pyridinyl, pyrimidinyl or piperidinyl;R.sup.2 is H, alkyl, aryl, or arylalkyl; andR.sup.4 is alkyl, heteroalkyl, aryl or heteroaryl, wherein the aryl or heteroaryl group can be mono- or bi-cyclic.
    Type: Grant
    Filed: October 14, 1992
    Date of Patent: August 23, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Ruth F. Nutt, Daniel F. Veber
  • Patent number: 5340802
    Abstract: Peptide analog type-B CCK receptor ligands or pharmaceutically-acceptable salts thereof, which are useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and for the treatment of shock, respiratory and cardiocirculatory insufficiencies.
    Type: Grant
    Filed: January 29, 1993
    Date of Patent: August 23, 1994
    Assignee: Abbott Laboratories
    Inventors: Kazumi Shiosaki, Alex M. Nadzan, David S. Garvey, Youe-Kong Shue, Mark S. Brodie, Mark W. Holladay, John Y.-L. Chung, Michael D. Tufano, Paul D. May
  • Patent number: 5338726
    Abstract: Compounds are disclosed which inhibit endothelin converting enzyme. These compounds are useful for treating hypertension, congestive heart failure, myocardial infarction, reperfusion injury, coronary angina, cerebral vasospasm, acute renal failure, non-steroidal antiinflammatory drug induced gastric ulceration, cyclosporin induced nephrotoxicity, endotoxin-induced toxicity, asthma and atherosclerosis.
    Type: Grant
    Filed: September 29, 1992
    Date of Patent: August 16, 1994
    Assignee: Abbott Laboratories
    Inventors: Kazumi Shiosaki, Andrew S. Tasker, Terry J. Opgenorth
  • Patent number: 5338723
    Abstract: A fibrinogen receptor antagonist of the formula ##STR1## wherein XX represents a synthetic alpha-amino acid containing a linear side chain and ZZ represents a sequence of 1, 2, 3 or 4 amino acids.
    Type: Grant
    Filed: September 21, 1992
    Date of Patent: August 16, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Ruth F. Nutt, Stephen F. Brady, Daniel F. Veber, Mark E. Duggan
  • Patent number: 5336757
    Abstract: A novel peptide, polydiscamide A, has been isolated from a marine sponge. This compound, and its derivatives, are useful as antibacterial agents.
    Type: Grant
    Filed: February 7, 1992
    Date of Patent: August 9, 1994
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Nanda K. Gulavita, Sarath P. Gunasekera, Shirley A. Pomponi, Ross E. Longley, Peter J. McCarthy
  • Patent number: 5336758
    Abstract: The subject invention relates to a peptide having the amino acid sequence Glu-Ile-Cys-Thr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro or portions thereof. This peptide is derived from, or based upon, a region of a relatively conserved epitope of HIV-1 reverse transcriptase. The peptide may be utilized in the treatment of patients having human immunodeficiency virus or in the prevention of infection of those individuals who have been exposed to the disease, yet have not become sero-positive. The preparation containing the peptide may be administered either subcutaneously, intramuscularly or intravenously.
    Type: Grant
    Filed: March 9, 1990
    Date of Patent: August 9, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Anne Hosmalin, Mario S. Clerici, Ronald N. Germain, Gene Shearer, Bernard Moss, Charles D. Pendleton
  • Patent number: 5334583
    Abstract: Described are the use of hexopyranose compounds of the formula I ##STR1## for the prophylaxis and treatment of virus infections, and novel pharmaceutical preparations especially suitable for the use in accordance with the invention.The substituents in formula I have the meanings given in the claims.
    Type: Grant
    Filed: December 2, 1992
    Date of Patent: August 2, 1994
    Assignee: Ciba-Geigy Corp.
    Inventors: Bohumir Lukas, Karl H. S. Ruppin
  • Patent number: 5334506
    Abstract: Compounds of the formula I ##STR1## in which X denotes a hydrogen atom, a group which irreversibly masks the terminal amino group, or a protecting group which is conventional in peptide chemistry, such as, for example, Boc-, Z- or Fmoc-,A and B may be identical or different and denote an alpha- beta- or gamma-amino acid which comprises 2 to 15 carbon atoms and up to 4 nitrogen atoms, 2 sulfur atoms and 6 oxygen atoms and whose side chain may be substituted, and B, if appropriate, denotes a dipeptide formed from these amino acids,C denotes arginine, Lysine, tyrosine, phenylalanine or tryptophane, and their homologs,R.sub.1 and R.sub.2 are identical or different and denote a hydrogen atom or an alkyl radical having up to 4 carbon atoms,R.sub.3 to R.sub.8 are identical or different and denote hydrogen, an alkyl radical, an alkoxy radical or a halogen radical,Y denotes oxygen, andAn.sup.- denotes an anion, and their water-soluble salts, and a process for their preparation are described.
    Type: Grant
    Filed: October 30, 1991
    Date of Patent: August 2, 1994
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Werner Stuber, Dieter Schnaitmann
  • Patent number: 5331090
    Abstract: Synthetic polypeptides corresponding to the B lymphocyte CR2 receptor binding site present on a CR2 ligand are disclosed together with polypeptide aggregates, compositions, anti-polypeptide antibodies and methods of preparing and using the polypeptides and antibodies.
    Type: Grant
    Filed: September 8, 1989
    Date of Patent: July 19, 1994
    Assignee: California Institute of Biological Research
    Inventor: Waldemar Lernhardt
  • Patent number: 5331092
    Abstract: A process of preparation of collagen containing in major proportion insoluble collagen is disclosed, including rinsing and washing the collagenic tissue, acidifying the ground material pH value 1 to 4 to get a collagenic paste which is diluted in a diluting solution to get the collagen gel having a concentration in collagen lower than about 2.5 by weight expressed in dry collagen, and performing a shearing stirring at high speed producing ultrasonic effect to get a substantially homogeneous collagenic gel. The collagen has improved mechanical resistance and thermal stability.
    Type: Grant
    Filed: November 6, 1992
    Date of Patent: July 19, 1994
    Assignee: Coletica
    Inventors: Alain Huc, Rene Gimeno
  • Patent number: 5328900
    Abstract: Disclosed are novel peptide and pseudopeptide derivatives and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.
    Type: Grant
    Filed: October 15, 1992
    Date of Patent: July 12, 1994
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Scott I. Klein, Bruce F. Molino
  • Patent number: 5328899
    Abstract: Human Neuropeptide Y (NPY) has the formula: H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro- Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile- Thr-Arg-Gln-Arg -Tyr-NH.sub.2. Porcine and rat NPY have the same sequence except for Leu instead of Met in the 17-position. Porcine PYY is homologous having 11 different residues. NPY analogs and N-terminally-shortened fragments, e.g. NPY(18-36), which contain one or more specific D-isomer substitutions for the naturally occurring residues (as well as pharmaceutically acceptable salts thereof), dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals, including humans, to substantially lower blood pressure over an extended period of time or to counteract hypertension.
    Type: Grant
    Filed: May 12, 1992
    Date of Patent: July 12, 1994
    Assignees: The Salk Institute for Biological Studies, The Regents of the University of California
    Inventors: Jaroslav H. Boublik, Jean E. F. Rivier, Marvin R. Brown, Neal A. Scott